Pembrolizumab 400 mg every 6 weeks as firstline therapy for advanced melanoma KEYNOTE555 Results from cohort B of an openlabel phase 1 stud

G CohenB RapoportS ChanPaul RuffA AranceE et al2025-03-03WOS1932-6203https://hdl.handle.net/10539/44043Pembrolizumab 400 mg every 6 weeks as firstline therapy for advanced melanoma KEYNOTE555 Results from cohort B of an openlabel phase 1 studJournal Article